![](/assets/images/hcp/branding-bar.png)
CONSIDER AMYLOID PLAQUE BIOMARKER TESTING AS THE NEXT STEP FOR YOUR PATIENTS
![Patient profile with text surrounding: family history of AD, trouble concentrating, misplacing items](/assets/images/hcp/clara_v4.png)
Amyvid is used to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline. Amyvid is an adjunct to other diagnostic evaluations.3
Consider Amyvid for your patients who:
- Are displaying signs of cognitive impairment where AD is suspected3
- Have undergone an initial workup (labs, cognitive assessment, EEG, MRI)4,5
- Are concerned about memory slips
- Want to know what may be the cause of their cognitive impairment
- Are open to treatment and want an informed diagnosis to inform next steps
EEG = electroencephalogram; MRI=magnetic resonance imaging.
SELECT SAFETY INFORMATION
Risk for Image Misinterpretation and Other Errors
See how Amyvid can fit into your patient’s diagnostic plan
References:
- Gauthier S, Rosa-Neto, P, Morais JA, et al. World Alzheimer Report 2021: Journey Through the Diagnosis of Dementia. London, England: Alzheimer’s Disease International; 2021. Accessed January 25, 2023. https://www.alzint.org/u/World-Alzheimer-Report-2021.pdf
- DiBenedetti DB, Slota C, Wronski SL, et al. Assessing what matters most to patients with or at risk for Alzheimer’s and care partners: a qualitative study evaluating symptoms, impacts, and outcomes. Alzheimers Res Ther. 2020;12(1):90. doi: 10.1186/s13195-020-00659-6
- Amyvid (florbetapir F 18 injection). Prescribing Information. Lilly USA, LLC.
- Hort J, O'Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010;17(10):1236-1248.
- Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
- McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging Alzheimer's association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement.2011;7(3):263-269.